Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2016

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Lerebours F et al., Cancer. 2016 Oct;122(19):3032-40

2016

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

Péron J et al., Oncotarget. 2016 Dec 13;7(50):82953-82960.

2016

Applying the longitudinal model from item response theory to assess health-related quality of life in the PRODIGE 4/ACCORD 11 randomized trial.

Barbieri A et al., Med Decis Making. 2016 Jul;36(5):615-28.

2016

The ConSoRe project supports the implementation of big data in oncology [article in French]

Heudel P et al., Bull Cancer. 2016 Nov;103(11):949-95

2016

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Delaloge S et al., Ann Oncol. 2016 Sep;27(9):1725-32.

2016

Routinely collected data may usefully supplement randomised controlled data on treatment effects for mortality.

Pérol D et al., BMJ 2016;355:i6745

2016

Reply to 'The potential and perils of observational studies' by M. Buyse et al.

Delaloge S et al., Ann Oncol. 2016 Nov 9.

2016

Unicancer ESMÉ Program: how to use real world data to build a new research model in oncology [article in French]

Cailliot C et al., Innovations & Thérapeutiques en Oncologie. 2016;2(4):164-166.

2016

Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with advanced Solid Tumors: A UNICANCER Study.

Diéras V et al., Oncol Ther (2016) 4: 211.

2016

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Imbs DC et al., Cancer Chemother Pharmacol. 2016 Feb;77(2):385-92.